The most common reason people don’t start GLP-1 therapy isn’t that they can’t get a prescription. It’s that the cost without insurance — $900 to $1,600 per month for brand-name medications — makes it unreachable for most people.
The good news: brand-name isn’t the only option, and the gap between “GLP-1 is unaffordable” and “GLP-1 is accessible” has narrowed considerably in the last two years.
Here are the actual paths available in 2026.
Path 1: Compounded Semaglutide Through Telehealth
This is how most people without insurance access GLP-1 today, and it’s the path I use.
Compounded semaglutide contains the same active ingredient as Ozempic (semaglutide), produced by a licensed compounding pharmacy rather than Novo Nordisk. The compound is prescribed through a telehealth platform by a licensed provider.
Cost: $200 to $400 per month depending on dose. No insurance required.
Process: Complete an online intake form (medical history, health goals, current medications). A licensed provider reviews your case. If you’re a candidate, a prescription is sent to a licensed compounding pharmacy and medication ships to your door within a week of approval.
Requirements: You need to be a candidate medically — a BMI of 27 or higher with a weight-related condition, or a BMI of 30 or higher, is the standard clinical threshold. Some telehealth providers are more flexible. Certain conditions (history of thyroid cancer, pancreatitis, or specific other diagnoses) are contraindications.
What you’re trading: The brand-name FDA-approved drug for a compounded version of the same active ingredient. Licensed pharmacy, licensed prescriber, same mechanism of action, lower cost. Not FDA-approved as a finished drug product — that’s the distinction that matters to some people.
The program I use is ShedRX. Details here.
Affiliate link — I may earn a commission at no extra cost to you.
Path 2: Manufacturer Savings Programs
Novo Nordisk (Ozempic and Wegovy) and Eli Lilly (Mounjaro and Zepbound) offer savings programs that can significantly reduce cost for people who have commercial insurance that partially covers the drug.
Novo Nordisk savings card: Can reduce monthly cost to as low as $25 per month for eligible patients with commercial insurance. Not available for Medicare or Medicaid beneficiaries. Income limits apply.
Lilly’s savings program for Zepbound: Similar structure. Zepbound was specifically priced lower than Mounjaro when launched to improve access.
These programs are only useful if you have commercial insurance that covers the drug at least partially. Without any insurance coverage, the savings card doesn’t apply.
Path 3: Traditional Doctor Prescription Plus GoodRx or Similar
GoodRx and similar discount programs negotiate lower prices with pharmacies for cash-pay customers. For GLP-1 medications, the discounts are real but the resulting cost is still high — typically $700 to $900 per month for Ozempic even with a discount card.
This path makes more sense for lower-cost medications than for GLP-1. It’s worth checking, but it doesn’t solve the access problem for most people.
Path 4: Getting Insurance to Cover It
Some insurance plans cover GLP-1 for type 2 diabetes (Ozempic and Mounjaro are approved for this indication) but not for weight loss alone. If you have type 2 diabetes or prediabetes, the insurance coverage picture is different than if you’re seeking it purely for weight loss.
For weight loss specifically, coverage varies significantly by plan and employer. Large employer plans have been adding GLP-1 coverage, while many are also restricting it due to cost. Medicare historically excluded weight loss drugs from coverage, though this is an active policy debate.
If you want to pursue insurance coverage, the process involves your primary care physician documenting medical necessity — typically requiring documented BMI, related conditions, and prior treatment attempts. Prior authorization is almost always required. The process can take weeks to months.
Path 5: Academic Medical Centers and Clinical Trials
Clinical trials for GLP-1 medications and related drugs are ongoing. Clinicaltrials.gov lists active trials that may provide access to GLP-1 medications at no cost in exchange for participation in research.
This is a real but limited path — trials have specific eligibility requirements, time commitments, and geographic constraints. For people who meet the criteria and live near participating centers, it’s worth investigating.
What Most People Without Insurance End Up Doing
Compounded semaglutide through telehealth. $200 to $400 per month. Same active ingredient as Ozempic. Provider oversight through the telehealth platform. Medication shipped monthly.
It’s not the path for everyone — some people want the brand-name product specifically, some have contraindications, some have conditions that require closer in-person medical supervision. But for healthy adults who meet the clinical criteria and don’t have insurance coverage, this is where the access gap closes.